Deborah H Fuller

List of Publications by Year
in descending order

83 papers	6,254 citations	101543 36 h-index	74163 75 g-index
96 all docs	96 docs citations	96 times ranked	6073 citing authors

#	Article	IF	Citations
1	In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. Human Gene Therapy, 2022, 33, 389-403.	2.7	5
2	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. ELife, 2022, 11, .	6.0	26
3	Letter to the Editor: Prior Infection with Coccidioidomycosis in Nonhuman Primates and Impact on Simian Immunodeficiency Virus Disease and Vaccine Immunogenicity. AIDS Research and Human Retroviruses, 2022, , .	1.1	0
4	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. PLoS Pathogens, 2022, 18, e1010155.	4.7	6
5	STING Is Required in Conventional Dendritic Cells for DNA Vaccine Induction of Type I T Helper Cell-Dependent Antibody Responses. Frontiers in Immunology, 2022, 13, 861710.	4.8	3
6	Recrudescence of Natural Coccidioidomycosis During Combination Antiretroviral Therapy in a Pigtail Macaque Experimentally Infected with Simian Immunodeficiency Virus. AIDS Research and Human Retroviruses, 2021, 37, 505-509.	1.1	2
7	Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques. Npj Vaccines, 2021, 6, 34.	6.0	7
8	Rapid progression is associated with lymphoid follicle dysfunction in SIV-infected infant rhesus macaques. PLoS Pathogens, 2021, 17, e1009575.	4.7	4
9	Effects of therapeutic vaccination on the control of SIV in rhesus macaques with variable responsiveness to antiretroviral drugs. PLoS ONE, 2021, 16, e0253265.	2.5	9
10	A Gut Reaction to SIV and SHIV Infection: Lower Dysregulation of Mucosal T Cells during Acute Infection Is Associated with Greater Viral Suppression during cART. Viruses, 2021, 13, 1609.	3.3	0
11	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	28.9	131
12	B cell activating factor (BAFF) from neutrophils and dendritic cells is required for protective B cell responses against Salmonella typhimurium infection. PLoS ONE, 2021, 16, e0259158.	2.5	6
13	A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques. Frontiers in Immunology, 2021, 12, 800723.	4.8	4
14	Transient Immune Activation in BCG-Vaccinated Infant Rhesus Macaques Is Not Sufficient to Influence Oral Simian Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2020, 222, 44-53.	4.0	10
15	An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Science Translational Medicine, 2020, 12, .	12.4	181
16	Preparing for Pandemics: RNA Vaccines at the Forefront. Molecular Therapy, 2020, 28, 1559-1560.	8.2	8
17	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	28.9	420
18	De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science, 2020, 370, 1208-1214.	12.6	172

#	Article	IF	Citations
19	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. Frontiers in Immunology, 2020, 11, 984.	4.8	9
20	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. Journal of Virology, 2020, 94, .	3.4	6
21	Amplifying RNA Vaccine Development. New England Journal of Medicine, 2020, 382, 2469-2471.	27.0	81
22	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathogens, 2020, 16, e1008377.	4.7	14
23	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. Frontiers in Immunology, 2020, 11, 626464.	4.8	4
24	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports, 2019, 28, 877-895.e6.	6.4	36
25	Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. Journal of Virology, 2019, 93, .	3.4	27
26	Mucosal T Helper 17 and T Regulatory Cell Homeostasis Correlate with Acute Simian Immunodeficiency Virus Viremia and Responsiveness to Antiretroviral Therapy in Macaques. AIDS Research and Human Retroviruses, 2019, 35, 295-305.	1.1	10
27	Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. Human Vaccines and Immunotherapeutics, 2018, 14, 1820-1831.	3.3	25
28	Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation. PLoS ONE, 2018, 13, e0198154.	2.5	18
29	Early cellular innate immune responses drive Zika viral persistence and tissue tropism in pigtail macaques. Nature Communications, 2018, 9, 3371.	12.8	38
30	Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. Nature Biotechnology, 2017, 35, 667-671.	17.5	108
31	Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. Journal of Immunology, 2017, 198, 757-766.	0.8	23
32	Massively parallel de novo protein design for targeted therapeutics. Nature, 2017, 550, 74-79.	27.8	354
33	Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates. PLoS ONE, 2017, 12, e0189780.	2.5	23
34	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. PLoS Pathogens, 2016, 12, e1005409.	4.7	49
35	Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine, 2016, 34, 3500-3507.	3.8	26
36	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. Journal of Immunology, 2016, 196, 3064-3078.	0.8	56

#	Article	IF	Citations
37	Minor Antigen Vaccine-Sensitized DLI. Transplantation Direct, 2016, 2, e71.	1.6	0
38	Complex Minigene Library Vaccination for Discovery of Pre-Erythrocytic Plasmodium T Cell Antigens. PLoS ONE, 2016, 11, e0153449.	2.5	7
39	Laparoscopic Technique for Serial Collection of Para-Colonic, Left Colic, and Inferior Mesenteric Lymph Nodes in Macaques. PLoS ONE, 2016, 11, e0157535.	2.5	10
40	Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation. Transplantation, 2015, 99, 2083-2094.	1.0	7
41	Isolation, characterization, and functional analysis of ferret lymphatic endothelial cells. Veterinary Immunology and Immunopathology, 2015, 163, 134-145.	1.2	6
42	Rapid Loss of Th17 Cells after SIV Infection May Underlie Mucosal Dysfunction. AIDS Research and Human Retroviruses, 2014, 30, A48-A48.	1.1	0
43	Commentary: HIV Vaccine Trial Exploits a Dual and Central Role for Innate Immunity. Journal of Virology, 2014, 88, 11640-11643.	3.4	3
44	Functional characterization of ferret CCL20 and CCR6 and identification of chemotactic inhibitors. Cytokine, 2013, 61, 924-932.	3.2	7
45	A novel tetrameric gp3501â€“470 as a potential Epsteinâ€“Barr virus vaccine. Vaccine, 2013, 31, 3039-3045.	3.8	46
46	Optimizing Particle-Mediated Epidermal Delivery of an Influenza DNA Vaccine in Ferrets. , 2013, 940, 223-237.		12
47	â€˜Omics Investigations of HIV and SIV Pathogenesis and Innate Immunity. Current Topics in Microbiology and Immunology, 2012, 363, 87-116.	1.1	3
48	Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques. PLoS ONE, 2012, 7, e33715.	2.5	44
49	DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4+ T cells, but few subdominant epitope-specific CD8+ T cells. Vaccine, 2011, 29, 7483-7490.	3.8	6
50	GM-CSF Increases Mucosal and Systemic Immunogenicity of an H1N1 Influenza DNA Vaccine Administered into the Epidermis of Non-Human Primates. PLoS ONE, 2010, 5, e11021.	2.5	73
51	Particle-mediated DNA vaccines against seasonal and pandemic influenza viruses elicit strong mucosal antibody and T cell responses in the lung. Procedia in Vaccinology, 2010, 3, 2-11.	0.4	1
52	Oral Immunization with a Live Coxsackievirus/HIV Recombinant Induces Gag p24-Specific T Cell Responses. PLoS ONE, 2010, 5, e12499.	2.5	2
53	Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Review of Vaccines, 2009, 8, 1205-1220.	4.4	42
54	Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology, 2007, 364, 245-255.	2.4	18

#	Article	IF	Citations
55	Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods, 2006, 40, 86-97.	3.8	138
56	DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology, 2006, 348, 200-215.	2.4	31
57	Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. Virology, 2006, 354, 116-131.	2.4	5
58	Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine, 2005, 23, 4867-4878.	3.8	69
59	Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comparative Immunology, Microbiology and Infectious Diseases, 2003, 26, 373-388.	1.6	67
60	Multispecific Vaccine-Induced Mucosal Cytotoxic TLymphocytes Reduce Acute-Phase Viral Replication but Fail inLong-Term Control of Simian Immunodeficiency VirusSIVmac239. Journal of Virology, 2003, 77, 13348-13360.	3.4	101
61	Induction of Mucosal Protection against Primary, Heterologous Simian Immunodeficiency Virus by a DNA Vaccine. Journal of Virology, 2002, 76, 3309-3317.	3.4	110
62	Plasmid Vectors Encoding Cholera Toxin or the Heat-Labile Enterotoxin from Escherichia coli Are Strong Adjuvants for DNA Vaccines. Journal of Virology, 2002, 76, 4536-4546.	3.4	82
63	Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239. Journal of Virology, 2002, 76, 7187-7202.	3.4	185
64	Differences Between T Cell Epitopes Recognized After Immunization and After Infection. Journal of Immunology, 2002, 169, 4511-4521.	0.8	38
65	Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. Current Opinion in Molecular Therapeutics, 2002, 4, 459-66.	2.8	17
66	Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen. Journal of Immunology, 2000, 164, 4968-4978.	0.8	247
67	Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine, 2000, 19, 764-778.	3.8	329
68	HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunology Letters, 1999, 66, 189-195.	2.5	49
69	Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance. Journal of Virology, 1999, 73, 3292-3300.	3.4	58
70	DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from Lethal Challenge. Virology, 1998, 246, 134-144.	2.4	166
71	Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine, 1997, 15, 869-873.	3.8	133
72	Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine, 1997, 15, 924-926.	3.8	90

#	Article	IF	Citations
73	Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunology and Cell Biology, 1997, 75, 389-396.	2.3	69
74	Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Advanced Drug Delivery Reviews, 1996, 21, 3-18.	13.7	29
75	Induction of immunodeficiency virusâ€specific immune responses in rhesus monkeys following gene gunâ€mediated DNA vaccination. Journal of Medical Primatology, 1996, 25, 236-241.	0.6	57
76	DNA vaccines: A novel approach to immunization. International Journal of Immunopharmacology, 1995, 17, 79-83.	1.1	85
77	Use of DNAs Expressing HIV-1 Env and Noninfectious HIV-1 Particles to Raise Antibody Responses in Mice. Virology, 1995, 209, 147-154.	2.4	157
78	Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine, 1995, 13, 1427-1430.	3.8	274
79	Immune Responses to Hepatitis B Virus Surface and Core Antigens in Mice, Monkeys, and Pigs after AccellÂ® Particle-Mediated DNA Immunization. Annals of the New York Academy of Sciences, 1995, 772, 282-284.	3.8	24
80	A Qualitative Progression in HIV Type 1 Glycoprotein 120-Specific Cytotoxic Cellular and Humoral Immune Responses in Mice Receiving a DNA-Based Glycoprotein 120 Vaccine. AIDS Research and Human Retroviruses, 1994, 10, 1433-1441.	1.1	142
81	Examination of Parameters Affecting the Elicitation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic Immunization. DNA and Cell Biology, 1993, 12, 791-797.	1.9	199
82	DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11478-11482.	7.1	1,045
83	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	0